Harbour Investments, Inc. Seagen Inc. Transaction History

Harbour Investments, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	SELL	$191.51 - $216.16 $36,195 - $40,854	-189 Reduced 49.22%	195 $41,000
Q2 2023 Aug 14, 2023	SELL	$187.64 - $206.25 $26,269 - $28,875	-140 Reduced 26.72%	384 $73,000
Q1 2023 May 15, 2023	SELL	$127.59 - $203.08 $637 - $1,015	-5 Reduced 0.95%	524 $106,000
Q4 2022 Feb 15, 2023	BUY	$117.37 - $139.17 $4,460 - $5,288	38 Added 7.74%	529 $67,000
Q2 2022 Aug 15, 2022	SELL	$108.81 - $179.33 $8,160 - $13,449	-75 Reduced 13.25%	491 $87,000

Q4 2021 Feb 16, 2022	SELL	$142.57 - $190.86 $70,144 - $93,903	-492 Reduced 46.5%	566 $88,000
Q3 2021 Nov 15, 2021	BUY	$142.45 - $169.82 $23,219 - $27,680	163 Added 18.21%	1,058 $180,000
Q2 2021 Aug 16, 2021	SELL	$135.08 - $161.1 $3,647 - $4,349	-27 Reduced 2.93%	895 $141,000
Q1 2021 Aug 17, 2021	BUY	$137.51 - $190.8 $126,509 - $175,536	920 Added 46000.0%	922 $128,000
Q1 2021 May 12, 2021	BUY	$137.51 - $190.8 $275 - $381	2 New	2 $0

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Harbour Investments, Inc., based on Form 13F filings with the SEC.

Stay updated on Harbour Investments, Inc. with notifications on news.